Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays

Saker, Kahina; Langlois‐Jacques, Carole; Morfin-Sherpa, Florence; Pozzetto, Bruno; Jérôme, Adnot; Alfaiate, Dulce; Bal, Antonin; Bergeret, Alain; Boibieux, A.; Florent, Bonnet; Gaëlle, Bourgeois; Bellanger, Florence; Caire, Eurydice; Bárbara, Cristina; Coriat, Pierre; Laurent, Césari; d’Aubarede, Constance; François, Durupt; Escuret, Vanessa; Fascia, Pascal; Fassier, Jean‐Baptiste; Fontaine, Juliette; Gaillot-Durand, Lucie; Gaymard, Alexandre; Gillet, Myriam; Godinot, Matthieu; Gueyffier, François; Guibert, Nicolas; Josset, Laurence; Lahousse, Matthieu; Lina, Bruno; Hélène, Lozano; Makhloufi, Djamila; Massardier-Pilonchéry, Amélie; Milon, Marie-Paule; Frédéric, Moll; Morfin, Florence; Narbey, David; Julie-Anne, Nazare; Fatima, Oria; Adèle, Paul; Perry, Marielle; Pitiot, Virginie; Mélanie, Prudent; Rabilloud, Muriel; Samperiz, Audrey; Schlienger, Isabelle; Simon, Chantal; Trabaud, Mary-Anne; Trouillet‐Assant, Sophie; Valette, Martine

doi:10.1016/j.cmi.2021.01.003

Cited by 14 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, they were detected in all 129 HCWs with documented SARS‐CoV‐2 infection 6 months before. These sera were further characterized, 82.9% ( n = 107) had IgG against the SARS‐CoV‐2 RBD domain (bioMérieux VIDAS®) [ 8 , 9 , 10 ] and only 48.8% ( n = 63) scored positive in a virus neutralization test (VNT) (Table 1 ), confirming previous findings regarding the relative short half‐life of neutralizing antibodies (nAbs) in subjects with mild disease [ 11 , 12 ].…”

supporting

confidence: 79%

Specific detection of memory T‐cells in COVID‐19 patients using standardized whole‐blood Interferon gammarelease assay

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

supporting

confidence: 79%

Specific detection of memory T‐cells in COVID‐19 patients using standardized whole‐blood Interferon gammarelease assay

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, durability of the humoral immune response has yet to be defined. To date, the longest observation period assessing the longevity of the antibody response has been of 6–8 months [ [7] , [8] , [9] ].…”

Section: Introductionmentioning

confidence: 99%

Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study

Masiá

Fernandez-González

Telenti

et al. 2021

Journal of Autoimmunity

View full text Add to dashboard Cite

Objectives Durability of the humoral immune response to SARS-CoV-2 has yet to be defined. We longitudinally evaluated during a 12-month period the antibody responses to SARS-CoV-2, and analysed predictors of antibody titres decline and seroreversion. Methods Prospective study conducted in a cohort of patients hospitalized for microbiologically-confirmed COVID-19. Blood and nasopharyngeal samples were sequentially obtained during hospital stay and at 1, 2, 6 and 12 months after patients’ discharge for measuring anti-spike (S) and anti-nucleocapsid (N) IgG antibody levels and SARS-CoV-2 RNA, respectively. Results 80 non-vaccinated patients were analysed. At month 12 after discharge, 73 (91.2%) patients exhibited detectable S-IgG and 35 (43.8%) N-IgG antibody titres. A gradual wane was observed in S-IgG and N-IgG antibody titres. Linear regression showed that S-IgG decline was positively associated with peak antibody titres (coefficient [95% CI] 0.059 [0.05–0.067], p < 0.001), inversely with WHO severity score (coefficient [95% CI] −0.042 [-0.079/-0.004], p = 0.033), and there was a trivial positive association with age (coefficient [95% CI] 0.002 [0–0.005], p = 0.10); N-IgG decline was positively associated with peak antibody titres (coefficient [95% CI] 0.091 [0.078–0.105], p < 0.001). Logistic regression showed that seroreversion for S-IgG was inversely associated with peak S-IgG (OR 0.19; 95% CI, 0.04-0.45; p = 0.004); seroreversion for N-IgG was inversely associated with peak N-IgG (OR 0.71; 95% 0.53–0.90; p = 0.009) and positively with cycle threshold of RT-PCR (OR 1.14; 95% CI, 1.00–1.33; p = 0.062). Conclusion Anti-spike IgG antibodies remain detectable one year after hospitalization for COVID-19. Higher peak antibody titres and disease severity were associated with increased durability of detectable antibodies.

show abstract

“…All studies testing total Ig, employing pan‐immunoglobulin assays measuring IgG, IgM and IgA isotypes, could demonstrate positivity at all test time points measured, 25 , 26 , 27 , 28 , 29 , 30 , 31 up to 32–33 weeks post positive PCR 26 despite a considerable variability of test time points, targeted antigens and assays used across studies. Gudbjartsson et al.…”

Section: Persistence Of Humoral Responsementioning

confidence: 97%

Persistence of humoral response upon SARS‐CoV‐2 infection

Knies

Braun

Kimpel

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary SARS‐CoV‐2 continues to leave its toll on global health and the economy. Management of the pandemic will rely heavily on the degree of adaptive immunity persistence following natural SARS‐CoV‐2 infection. Along with the progression of the pandemic, more literature on the persistence of the SARS‐CoV‐2‐specific antibody response is becoming available. Here, we summarize findings on the persistence of the humoral, including neutralizing antibody, response at three to eight months post SARS‐CoV‐2 infection in non‐pregnant adults. While the comparability of the literature is limited, findings on the detectability of immunoglobulin G class of antibodies (IgG) were most consistent and were reported in most studies to last for six to eight months. Studies investigating the response of immunoglobins M and A (IgM, IgA) were limited and reported mixed results, in particular, for IgM. The majority of studies observed neutralizing antibodies at all time points tested, which in some studies lasted up to eight months. The presence of neutralizing antibodies has been linked to protection from re‐infection, suggesting long‐term immunity to SARS‐CoV‐2. These neutralizing capacities may be challenged by emerging virus variants, but mucosal antibodies as well as memory B and T cells may optimize future immune responses. Thus, further longitudinal investigation of PCR‐confirmed seropositive individuals using sensitive assays is warranted to elucidate the nature and duration of a more long‐term humoral response.

show abstract

Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays

Cited by 14 publications

References 7 publications

Specific detection of memory T‐cells in COVID‐19 patients using standardized whole‐blood Interferon gammarelease assay

Specific detection of memory T‐cells in COVID‐19 patients using standardized whole‐blood Interferon gammarelease assay

Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study

Persistence of humoral response upon SARS‐CoV‐2 infection

Contact Info

Product

Resources

About